Moxifloxacin 0.5% ophthalmic solution in bacterial conjunctivitis

Drugs

Volumn 71, Issue 1, 2011, Pages 89-99

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PLACEBO; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONJUNCTIVITIS; CORNEA EPITHELIUM; CROSS RESISTANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENZYME INHIBITION; EYE IRRITATION; EYE PAIN; EYE SURGERY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZED CHILD; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, BACTERIAL; EYE; HUMANS; MULTICENTER STUDIES AS TOPIC; OPHTHALMIC SOLUTIONS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 78650805554     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11205840-000000000-00000     Document Type: Article

References (48)

1. Høvding G. Acute bacterial conjunctivitis. Acta Ophthal-mol 2008 Feb; 86 (1): 5-17.
2. Rose P. Management strategies for acute infective con-junctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007 Aug; 8 (12): 1903-21.
3. Lichtenstein SJ, Dorfman M, Kennedy R, et al. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 2006 Jan/Feb; 43 (1): 19-26.
4. Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of State Departments of Health. J Pediatr Ophthalmol Strabismus 2007 Mar/Apr; 44 (2): 101-5.
5. Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. Epub 2010 Jun 8.
6. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med 2008 Jul; 75 (7): 507-12.
7. Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Oph-thalmol 2005 Nov; 50 (6 Suppl. 1): S16-31.
8. Pestova E, Millichap JJ, Noskin GA, et al. Intracellular tar-gets of moxifloxacin: a comparison with other fluoroquin-olones. J Antimicrob Chemother 2000 May; 45 (5): 583-90.
9. Vigamox 5mg/ml eye drops, solution: EU summary of pro-duct characteristics. Hunenberg, Switzerland: Alcon, 2009.
10. Sosa AB, Epstein SP, Asbell PA. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. Cornea 2008 Sep; 27 (8): 930-4.
11. Donaldson KE, Marangon FB, Schatz L, et al. The effect of moxifloxacin on the normal human cornea. Curr Med Res Opin 2006 Oct; 22 (10): 2073-80.
12. Sueke H, Kaye S, Neal T, et al. Minimum inhibitory con-centrations of standard and novel antimicrobials for isolates from bacterial keratitis. Invest Ophthalmol Vis Sci 2010 May; 51 (5): 2519-24.
13. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: na-tionwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008 Jun; 145 (6): 951-8.
14. Ohnsman C, Ritterband D, O'Brien T, et al. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin 2007 Sep; 23 (9): 2241-9.
15. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009 Aug; 53 (8): 3552-60.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 7th ed. Wayne (PA): Clinical and Laboratory Standards Institute, 2006: M7-A7.
17. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility testing [online]. Available from URL: http://www.bsac.org.uk/-db/-docu ments/Version-9.1-March-2010-final.pdf [Accessed 2010 Jul 2].
18. Wagner RS, Granet DB, Lichtenstein SJ, et al. Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides to-bramycin and gentamicin. Clin Ophthalmol 2010; 4: 41-5.
19. Lichtenstein SJ, Wagner RS, Jamison T, et al. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv Ther 2007 Sep/Oct; 24 (5): 1098-111.
20. D'Arienzo PA, Wagner RS, Jamison T, et al. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant Gram-positive conjunctival pathogens. Adv Ther 2010; 27 (1): 1-9.
21. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmaco-dynamic characteristics. Pharmacotherapy 2000 Mar; 20 (3): 245-56.
22. Mason BL, Alfonso EC, Miller D. In-use study of potential bacterial contamination of ophthalmic moxifloxacin. J Cataract Refract Surg 2005 Sep; 31 (9): 1773-6.
23. Yamada M, Yoshida J, Hatou S, et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br J Ophthalmol 2008 Jun; 92 (6): 848-51.
24. Park SH, Lim J-A, Choi J-S, et al. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea 2009 Jan; 28 (1): 68-72.
25. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquino-lones. Surv Ophthalmol 2004 Mar; 49 Suppl. 2: S79-83.
26. Marshall B, Cupp G, Foster K, et al. Moxifloxacin treat-ment of conjunctivitis: microbial effects beyond the eye [abstract no. C2-103 plus poster]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA).
27. McDermott M, Wheater M. In vitro comparison of the ef-fects of clinically available ophthalmic solutions of gati-floxacin 0.3% and moxifloxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression. Cornea 2006 Oct; 25 (9 Suppl. 2): S25-30.
28. Tsai T-H, Chen W-L, Hu F-R. Comparison of fluoroquin-olones: cytotoxicity on human corneal epithelial cells. Eye 2010 May; 24 (5): 909-17.
29. Kim S-Y, Lim J-A, Choi J-S, et al. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007 Jul; 26 (6): 720-5.
30. Price MO, Price Jr FW, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg 2005 Nov; 31 (11): 2137-41.
31. Burka JM, Bower KS, Vanroekel RC, et al. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photo-refractive keratectomy. Am J Ophthalmol 2005 Jul; 140 (1): 83-7.
32. Yee RW, Setabutr P, Foltermann MO, et al. The effects of topical moxifloxacin 0.5% ophthalmic solution and gati-floxacin 0.3% solution on corneal healing after bilateral photorefractive keratectomy. Cornea 2006 Oct; 25 (9 Suppl. 2): S8-11.
33. Torkildsen G, Proksch JW, Shapiro A, et al. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin Oph-thalmol 2010; 4: 331-41.
34. Torkildsen G, O'Brien TP. Conjunctival tissue pharmaco-kinetic properties of topical azithromycin 1% and moxiflox-acin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clin Ther 2008 Nov; 30 (11): 2005-14.
35. Wagner RS, Abelson MB, Shapiro A, et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol 2005 Sep; 123 (9): 1282-3.
36. Kim DH, Stark WJ, O'Brien TP, et al. Aqueous penetra-tion and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005 Nov; 112 (11): 1992-6.
37. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005 Mar; 112 (3): 466-9.
38. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005 Nov; 24 (8): 955-8.
39. McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006 Jun; 113 (6): 955-9.
40. Holland EJ, Lane SS, Kim T, et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxi-floxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 2008 Apr; 27 (3): 314-9.
41. Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007 Aug; 144 (2): 315-8.
42. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxi-floxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005 Jan; 123 (1): 39-44.
43. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006; 26 (2): 191-5.
44. Robertson SM, Curtis MA, Schlech BA, et al. Ocular phar-macokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005; 50 (6 Suppl. 1): S32-45.
45. Gross RD, Lichtenstein SJ, Schlech BA, et al. Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (Vigamox™) using b.i.d. dosing. Today's Ther Trends 2003; 21 (2): 227-37.
46. Granet DB, Dorfman M, Stroman D, et al. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pe-diatr Ophthalmol Strabismus 2008 Nov/Dec; 45 (6): 340-9.
47. Shimomura Y, Ohashi Y, Matsumoto K, et al. Phase III comparative study of moxifloxacin ophthalmic solution in bacterial conjunctivitis (multi center, double masked study) [in Japanese]. Atarashii Ganka 2007; 24 (10): 1381-94.
48. Alcon, Inc. Vigamox® (moxifloxacin hydrochloride oph-thalmic solution) 0.5% as base [online]. Available from URL: http://ecatalog.alcon.com/ pi/Vigamox-us-en.pdf [Accessed 2010 Jul 2]